Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00. Tycho Peterson has given his Buy rating due to a combination ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...

US diagnostic company Exact Sciences has announced its blood-based colorectal cancer (CRC) screening test algorithm showed a sensitivity of 88% for colorectal cancer and 31% for advanced ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...

On Monday, Exact Sciences (NASDAQ:EXAS) Corporation (NASDAQ:EXAS) shares received a reaffirmed Buy rating and a steady price target of $75 from Canaccord Genuity. The endorsement comes following ...

A liquid biopsy test for colon cancer made by Exact Sciences detected 88.3% of cancers and 31.2% of advanced precancers in a study of some 3,000 samples, STAT’s Jonathan Wosen writes.